Top Low Price Stocks To Buy Right Now

September may be considered as, historically, the worst month for the market, but MoneyShow’s Howard R. Gold still wants to share five other important obstacles he thinks are also standing in the way.

While you and I were enjoying the last rays of summer sunshine, the pundits, gurus, and Twitter addicts have sounded the warning bell for a rocky fall.

The Standard & Poor’s 500 index (SPX) fell 4.5% from its August peak, the Dow Jones Industrial Average lost 5.4%, and emerging markets have been pummeled.

But the pundits say several big events—mostly political—could make things even worse during the historically weakest month for stocks.

How big an impact? Let’s review them one by one.

1. Syrian crisis. President Obama has asked Congress to approve limited military action against Syria in retaliation for the alleged use of chemical weapons against civilians by President Bashar al-Assad.

After much hemming and hawing, I think he’ll get Congressional approval and will then launch cruise missiles against selected targets. (On Wednesday, the Senate Foreign Relations Committee authorized military action by a 10-7 vote.) It will go on for a couple of days, the rhetoric will be heated, there may be some limited retaliation against US or Israeli targets, but it won’t lead to a regional war. Or if he doesn’t get the votes, there may be no fighting at all.

Top Low Price Stocks To Buy Right Now: Ryland Group Inc (RYL)

The Ryland Group, Inc., incorporated on March 28, 1967, is a homebuilders and a mortgage-finance company. In addition, Ryland Mortgage Company and its subsidiaries, and RMC Mortgage Corporation (collectively referred to as RMC) provide mortgage financing and related services. All of the Company’s business is conducted and located in the United States. The Company’s operations span aspects of the home buying process from design, construction and sale to mortgage origination, title insurance, escrow and insurance services. During the year ended December 31, 2012, the homebuilding operations were consisted of approximately 97% of consolidated revenues. The homebuilding segments generate their revenues from sales of completed homes, with sales of land and lots. The Company builds homes for entry-level buyers, as well as for first- and second-time move-up buyers. In July 2012, the Company acquired Charlotte and Raleigh operations and assets of Timberstone Homes. In December 201 2, the Company acquired Phoenix operations and assets of Trend Homes. In June 2013, Ryland Group Inc acquired LionsGate Homes Corp. Effective July 19, 2013, Ryland Group Inc acquired Cornell Homes, a media-based construction company.

Homebuilding

The Company’s homes are built on-site and marketed in four geographic regions or segments: North, Southeast, Texas and West. Its North segment includes Baltimore, Chicago, Indianapolis, Minneapolis, Northern Virginia and Washington, D.C. Its Southeast include Atlanta, Charleston, Charlotte, Orlando and Tampa. Texas includes Austin, Houston and San Antonio. West includes Denver, Las Vegas and Southern California. During 2012, within each of those segments, the Company operated in the metropolitan areas of North, Southeast, Texas and West. Each of its homebuilding divisions across the country consists of a division president; a controller; management personnel focused on land entitlement, acquisition and deve lopment, sales, construction, customer service and purchasin! g, and accounting and administrative personnel. The Company markets attached and detached single-family homes. In the Company’s single-family detached home communities, it offers at least four different floor plans. The Company’s attached home communities offer different floor plans with two, three or four bedrooms. The Company relies on its own architectural staff and also engages unaffiliated architectural firms to develop new designs. Homebuyers are able to customize certain features of their homes by selecting from options and upgrades displayed in the Company’s model homes and design centers. In all of the Company’s communities, a range of options is available to homebuyers for additional charges. The number and complexity of options increase with the size and base selling price of the home. During 2012, custom options contributed 16.9% of homebuilding revenues.

The Company’s financial services segment provides mortgage-related products and services, as wel l as title, escrow and insurance services, to its homebuyers. The Company’s financial services segment includes RMC, RH Insurance Company, Inc. (RHIC), LPS Holdings Corporation and its subsidiaries (LPS), and Columbia National Risk Retention Group, Inc. (CNRRG). By aligning its operations with the Company’s homebuilding segments, the financial services segment leverages this relationship to offer its lending services to homebuyers.

During 2012, RMC’s mortgage origination operations consisted of the Company’s homebuilder loans, which were originated in connection with sales of the Company’s homes. During 2012, mortgage operations originated 3,039 loans, which used for purchasing homes built by the Company and for purchasing homes built by others, purchasing existing homes or refinancing existing mortgage loans. RMC arranges various types of mortgage financing, including conventional, Federal Housing Administration (FHA) and Veterans Administration (VA) mortgages, with various fixed- and adjustable-rate features. The Compa! ny sells ! the loans it originates, along with the related servicing rights, to others. Cornerstone Title Company, doing business as Ryland Title Company, is a 100 % subsidiary of RMC, provides escrow and title services and acts as a title insurance agent primarily for the Company’s homebuyers. As of December 31, 2012, it provided title services in Arizona, Colorado, Florida, Illinois, Indiana, Maryland, Minnesota, Nevada, Texas and Virginia. Ryland Insurance Services (RIS), a 100 % owned subsidiary of RMC, provides insurance services to the Company’s homebuyers. As of December 31, 2012, RIS was licensed to operate in all of the states in which the Company’s homebuilding segments operate. During 2012, it provided insurance services to 41.5 % of the Company’s homebuyers. CNRRG, a 100 %-owned subsidiary of the Company and some of its affiliates, offer insurance, specifically structural warranty coverage, to protect homeowners against liability risks arising in connection with the homebui lding business of the Company and its affiliates.

Advisors’ Opinion:

  • [By Louis Navellier]

    If we look at those stocks trading with single-digit P/E ratios right now, it becomes a very simple task to separate the wheat from the chaff. There are many well-known stocks trading at low P/E ratios that get horrible grades from our system and should be avoided:

    Ryland Homes (RYL) is a name you might hear discussed as a bargain, but the stock to a Sell back in November to a “D” and is best avoided. Standard Pacific (SPF) is another builder you should probably avoid as In spite of the low P/E ratio ,you probably want to avoid discount retailer Big Lots (BIG), as a Strong Sell this week.

    But fear not — there are some great companies with solid fundamentals that earn a Buy ranking from Portfolio Grader and are better candidates for a low-P/E portfolio.

  • [By Rick Aristotle Munarriz]

    Alamy You can never know in advance all the news that will move the market in a given week, but some things you can see coming. From the world’s largest consumer tech company posting its iEarnings to a pivotal end to the trading month, here are some of the things that will help shape the week that lies ahead on Wall Street. Monday — Growing Apples: Lately, Apple (AAPL) hasn’t been the growth stock darling that it was through most of the past decade, but it seems to be turning the corner. Apple is expected to post growth in revenue and earnings when it reports fiscal first quarter results on Monday afternoon. It’s not likely to be much. Analysts see revenue and earnings per share climbing by no more than 5 percent over last year’s holiday quarter. That may seem low given the success of the iPhone 5S and iPad Air that hit the market late last year. However, it’s been hard to overcome the slide in Mac and iPod sales. Tuesday — Comcast Stems the Bleeding: Another company showing renewed signs of life is Comcast (CMCSK). The country’s largest cable provider hasn’t had a problem growing its Internet and broadband phone services, but it’s been struggling since 2007 to keep its pay TV customers around. Comcast finally surprised investors earlier this month by announcing that it closed out the fourth quarter with more subscribers than it had three months earlier. This is the first time that Comcast has posted a sequential increase in video customers after 26 quarters of declines. Comcast reports on Tuesday. Hopefully it will shed some light on this welcome development, letting us know if the cord cutter fears are in the past. Wednesday — Are We Friends Again: It will be Facebook (FB) hoping that the market clicks “Like” on the leading social networking website’s quarterly financials on Wednesday. Facebook had a rocky start as a public company two years ago, going public at $38 and falling into the teens several months later. However, explosive top- and bottom-l

  • [By Erika Janowicz]

    Compass Point analyst Wilkes Graham updated his housing forecast:

    Graham increased assumed ROI’s to 9% on average from 7%. Reduced targeted sector price/ book from $190% to 170%. Expects 20-30% growth in starts and new home sales in 2012 and 2013 to stabilize in 2014 and on at approximately 10%. For covered builders, the analyst lowered estimates by 8% and lowered price targets by 10%. Compass Point expects 10% annual growth in single family starts and new home sales and 2-5% pricing growth. Downgraded DR Horton Inc. (NYSE: DHI) from Buy to Neutral and KB Home (NYSE: KBH) from Neutral to Sell. DR Horton’s and KB Home’s PT was lowered from $23.50 to $20.00 and from $17.50 to $14.00, respectively. Graham reiterated a Buy rating on Ryland Group Inc. (NYSE: RYL) and Standard Pacific Corp. (NYSE: SPF). The analyst raised the PT on Ryland from $50.00 to $50.50 and lowered the PT on Standard Pacific from $10.00 to $9.50. Compass Point reiterated a Neutral rating on Beazer Homes USA Inc. (NYSE: BZH), Hovnanian Enterprises Inc. (NYSE: HOV), Lennar Corp. (NYSE: LEN), PulteGroup, Inc. (NYSE: PHM), and Toll Brothers Inc. (NYSE: TOL). The price target for Beazer and Hovnanian was raised from $15.50 to $24.00 and $5.00 to $5.75, respectively. Graham lowered the PT for Lennar, Pulte, and Toll to $34.50, $17.00, and $31.00.

    This Week’s Data

  • [By Laura Brodbeck]

    Wednesday

    Earnings Expected From: Marriott International (NYSE: MAR), MetLife, Inc. (NYSE: MET), Facebook, Inc. (NASDAQ: FB), Garmin Ltd (NASDAQ: GRMN), Ryland Group, Inc. (NYSE: RYL) Economic Releases Expected: British consumer confidence, New Zealand Interest rate decision, US FOMC meeting announcement, German CPI, US GPD, US core CPI, US nonfarm employment change

    Thursday

Top Low Price Stocks To Buy Right Now: Aetrium Incorporated(ATRM)

Aetrium Incorporated designs, manufactures, and markets electromechanical equipment for the semiconductor industry to handle and test integrated circuits (ICs). The company provides test handler products, which incorporates thermal conditioning, contacting, and automated handling technologies to provide automated handling of ICs during production of test cycles; change kits to adapt test handlers to various IC package configurations or to upgrade installed equipment; and gravity feed test handlers. It also offers reliability test equipment, which provides structural performance data to aid in the evaluation and improvement of IC designs and manufacturing processes. The company sells its products to semiconductor manufacturers, and their assembly and test subcontractors through direct salespeople, independent sales representatives, and distributors in the United States, the United Kingdom, France, Germany, Italy, Korea, Japan, Taiwan, China, Thailand, Malaysia, Singapore, a nd the Philippines. Aetrium Incorporated was founded in 1982 and is based in North St. Paul, Minnesota.

Advisors’ Opinion:

  • [By Paul Ausick]

    Stocks on the Move: Aetrium Inc. (NASDAQ: ATRM) is up 156.2% at $12.40 following a positive report based on a recent management change and new products. Mediabistro Inc. (NASDAQ: MBIS) is down 17.4% at $3.41 as the stock gives back some of the 87% gain it scored yesterday. J.C. Penney Co. Inc. (NYSE: JCP) is up 7.7% at $10.08 on momentum from an insider stock purchase earlier this week.

Top Low Price Stocks To Buy Right Now: Cyan Inc (CYNI)

Cyan, Inc., incorporated on October 25, 2006, has carrier-grade networking solutions that transform legacy networks into open, high-performance networks. The Company’s solutions include high-capacity, multi-layer switching and transport platforms, as well as a carrier-grade software-defined networking platform and applications. The Company’s solutions enable network operators to virtualize their networks, accelerate service delivery. The Company has designed its solutions to provide a range of applications, including business Ethernet, Wireless and broadband support services and cloud connectivity. The Company also offer high-capacity, multi-layer switching and transport platforms, known as its Cyan Z-Series, that have been designed to support the multiple concurrent technologies used in regional and metro networks, including both Ethernet-based services, as well as optical services.

The Company’s Z-Series platforms have been designed to transport traff ic over network layer, utilizing both electrical and optical domains, to enable network operators to maximize network capacity at the lowest cost per bit. The Company’s customers range from service providers to high-performance data center and large, private network operators.

Advisors’ Opinion:

  • [By Lauren Pollock]

    Among the companies with shares expected to actively trade in Tuesday’s session are Cyan Inc.(CYNI), Neurocrine Biosciences Inc.(NBIX) and SandRidge Energy Inc.(SD)

Top Low Price Stocks To Buy Right Now: Antares Pharma Inc (ATRS)

Antares Pharma, Inc. (Antares) is a pharma company that focuses on self-injection pharmaceutical products and technologies and topical gel-based products. The Company’s subcutaneous and intramuscular injection technology platforms include Vibex disposable pressure-assisted auto injectors, Vision reusable needle-free injectors, and disposable multi-use pen injectors. In the injector area, it has licensed its reusable needle-free injection device for use with human growth hormone (hGH) to Teva, Ferring Pharmaceuticals BV (Ferring) and JCR Pharmaceuticals Co., Ltd. (JCR), with Teva and Ferring being its two primary customers. The Company has also licensed both disposable auto and pen injection devices to Teva for use in certain fields and territories and is engaged in product development activities for Teva utilizing these devices.

In the gel-based area, it received Food and Drug Administration (FDA) approval in December 2011 for its oxybutynin gel 3% product, Anturol, for the treatment of overactive bladder. Antares also has a licensing agreement with Watson Watson Pharmaceuticals, Inc. (Watson) under which Watson will commercialize its topical oxybutynin gel 3% product in the United States and Canada. Its gel portfolio also includes Elestrin (estradiol gel) in the United States for the treatment of moderate-to-severe vasomotor symptoms associated with menopause. Antares has designed disposable, pressure assisted auto injector devices to address acute medical needs, such as allergic reactions, migraine headaches, acute pain, emesis and other daily therapies.

Pressure Assisted Injection Devices

The Company’s Pressure Assisted Injection Devices consists of three products: reusable needle-free injectors, disposable pressure assisted auto injectors and disposable pen injectors. Reusable needle-free injectors deliver precise medication doses through high-speed, pressurized liquid penetration of the skin without a needle. The injector employs a disposable pl! astic needle-free syringe, which offers liquid medication delivery through an opening that is approximately half the diameter of a standard, 30-gauge needle.

Disposable pressure assisted auto injectors is a technology of controlled pressure delivery of drugs into the body utilizing a spring power source. The Vibex is designed to provide fast subcutaneous or intramuscular injections of up to 0.5ml with minimal discomfort and improved convenience in conjunction with the enhanced safety of a shielded needle. Disposable pen injectors are needle-based devices designed to deliver multiple injections from multi-dose drug cartridges. The devices contain mechanisms that specify the dose to be delivered by defining the amount of movement by the stopper in the cartridge with each device actuation.

The Vision/Tjet has been sold for use in more than 30 countries to deliver either insulin or hGH. The product features a reusable, spring-based power source and dis posable needle-free syringe, which acts as the pathway for the injectable drug through the skin and allows for viewing of the medication dose prior to injection. The product is also reusable, with each device designed to last for approximately 3,000 injections (or approximately two years) while the needle-free syringe, when used with insulin or hGH, is disposable after approximately one week when used by a single patient for injecting from multi-dose vials. The Vision/Tjet administers injectables by using a spring to push the active ingredient in solution or suspension through a micro-fine opening in the needle-free syringe. The opening is approximately half the diameter of a 30-gauge needle. The Vision/Tjet is primarily used in the United States, Europe, Asia and Japan.

Antares has designed disposable, pressure assisted auto injector devices to address acute medical needs, such as allergic reactions, migraine headaches, acute pain, emesis and other daily therap ies. Its Vibex disposable product combines a low-energy, spr! ing-based! power source with a hidden needle, which delivers up to 0.5ml of the needed drug solution subcutaneously or intramuscularly. Antares is also developing a Vibex MTX auto injector for delivery of methotrexate for treatment of rheumatoid arthritis. The Company’s multi use, disposable pen injector complements its portfolio of single-use pressure assisted auto injector devices. The disposable pen injector device is designed to deliver drugs by injection through needles from multi- dose cartridges. The disposable pen is in the stage of development where devices are being used in clinical evaluations.

Transdermal Products

The Company’s ATD system penetrates the skin to deliver a variety of treatments. The gels consist of a hydro-alcoholic base, including a combination of permeation enhancers. Products being developed/ commercialized include Anturol, Elestrin and Nestragel. Elestrin is a transdermal estradiol gel for the treatment of moderate-to-sever e vasomotor symptoms associated with menopause. Its other injectable drugs that are presently self-administered and may be suitable for injection with its systems include therapies for the prevention of blood clots and treatments for multiple sclerosis, migraine headaches, inflammatory diseases, impotence, infertility, acquired immune deficiency symdrome (AIDS) and hepatitis.

The Company competes with Ypsomed AG, SHL Group AB, OwenMumford Ltd., West Pharmaceuticals, Becton Dickinson, Haselmeir GmbH, Elcam Medical, Vetter Pharma, Bioject Medical Technologies Inc., The Medical House PLC, Watson, Abbott, Eli Lilly, Auxillium, Inc., Endo Pharmaceuticals, Teva, Mylan, Roxane, Bedford Labs, APP Pharmaceuticals, Hospira, Pfizer, GSK/Astellas, Warner Chilcott and Allergan.

Advisors’ Opinion:

  • [By MONEYMORNING]

    That’s not always the case. I watched as one well-known blogger on The Street sabotaged Antares Pharma (Nasdaq: ATRS) right after FDA approval for a new rheumatoid arthritis delivery system a few months ago, and it’s taken a long time for ATRS to finally recover. A similar thing happened to Sangamo Biosciences (Nasdaq: SGMO), which stopped my subscribers out of the stock. I advised them to buy right back into it, and we currently just exited with a 73.4% return on it.

  • [By Keith Speights]

    Antares Pharma (NASDAQ: ATRS  ) announced its first-quarter results  Wednesday morning but failed to impress the market. Shares were down around 3% in midday trading. Here are the highlights from the company’s results.

  • [By Keith Speights]

    1. Antares Pharma (NASDAQ: ATRS  )
    Antares has experienced a roller-coaster ride so far this year. The stock was up more than 10% early in January, then proceeded to fall by more than 20% by late February. Since then, Antares has clawed its way back and now stands up a little over 10% for the year. 

Top Low Price Stocks To Buy Right Now: Snam SpA (SRG)

Snam SpA is an Italy-based company engaged in the management of natural gas services. The Company is diversified into four operating segments. The Transportation segment covers transportation-related gas services, including capacity management and transportation of the gas at the entry points of the gas network to the redelivery points. It owns transportation infrastructures of gas pipelines. The Regasification segment is focused on extraction activities of natural gas, its liquefaction for transport by ship and subsequent regasification. The Storage segment covers deposits, gas treatment plants, compression plants and the operational dispatching system. The Distribution segment engages gas distribution through local transportation networks from delivery points at the metering and reduction stations to the gas distribution network redelivery points at the end customers. Additionally, Snam SpA as the parent company, focuses on planning, management, coordination and control of the group. Advisors’ Opinion:

  • [By Victor Selva]

    The Specialty Restaurant Group (SRG), which includes Bahama Breeze and The Capital Grille, has grown over the last couple of quarters. Eddie V’s Restaurants and Yard House might be meaningful long-term drivers, as we think most of the growth in the next years will come from the acquisition of those restaurants.

  • [By Tom Stoukas]

    Snam SpA (SRG) dropped the most in almost a year as Eni SpA sold an 11.7 percent stake in the owner of Italy’s biggest natural-gas network. Wm Morrison Supermarkets Plc tumbled the most in more than 14 months. Experian Plc jumped to a record after the world’s largest credit-checking company raised its dividend and announced a share buyback.

Top Low Price Stocks To Buy Right Now: Bank of Ireland (BKIR)

Bank of Ireland and its subsidiaries provide a range of banking and other financial services. The Company operates in five segments: Retail Ireland, Bank of Ireland Life, Retail UK, Corporate and Treasury and Group Centre. Group Centre includes capital management activities, unallocated Group support costs and the cost of the Credit Institutions. Retail Ireland distributes a range of financial products and services through the Bank’s branch operations in the Republic of Ireland and through its direct channels. The Company operates in the life and pensions market in Ireland through its wholly owned subsidiary New Ireland Assurance Company plc (NAIC).Retail UK consists of Business Banking in Great Britain and Northern Ireland, the branch network in Northern Ireland, the United Kingdom residential mortgage business and the business activities with the United Kingdom Post Office. Corporate and Treasury division consists of Corporate Banking, Global Markets and IBI Corporate Fin ance. Advisors’ Opinion:

  • [By Sarah Jones]

    In Dublin, Bank of Ireland (BKIR) slipped 3.4 percent to 14.1 euro cents and Permanent TSB Group Holdings Plc (IPM) tumbled 13 percent to 2.6 cents. Allied Irish Banks Plc (ALBK), which is owned by the state, slid 1.5 percent to 6.5 cents.

Top Low Price Stocks To Buy Right Now: Uroplasty Inc (UPI)

Uroplasty, Inc., incorporated in January 1992, is a medical device company that develops, manufactures and markets products for the treatment of voiding dysfunctions. The Company’s primary focus is on two products: the Urgent PC Neuromodulation system and Macroplastique Implants. The Urgent PC system is a United States Food and Drug Administration (FDA)-approved minimally invasive, office-based neuromodulation therapy for the treatment of overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency, and urge incontinence; and Macroplastique Implants a urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency (ISD). Outside of the United States, the Company’s Urgent PC is also approved for treatment of fecal incontinence, and Macroplastique is also approved for treatment of male stress incontinence and vesicoureteral reflux.

Urgent PC Neuromodulation System< /p>

Using a small-gauge needle electrode inserted above the ankle, the Urgent PC System delivers electrical impulses to the tibial nerve that travel to the sacral nerve plexus, a control center for pelvic floor and bladder function. Components of the Urgent PC system include a hair-width needle electrode, a lead set, and an external, handheld, battery-powered stimulator. For each 30-minute, office-based therapy session, the physician or other qualified healthcare provider inserts the needle electrode in the patient’s lower leg and connects the electrode to the stimulator. Typically, a patient undergoes 12 consecutive weekly treatment sessions, with follow-up maintenance treatments as required to sustain the therapeutic effect. The Company has received regulatory clearances for sale of the Urgent PC system in the United States, Canada and Europe. It also has launched its second generation Urgent PC system.

Macroplastique

Macroplas tique is designed to restore the patient’s urinary contine! nce immediately following treatment. Macroplastique is a soft-textured, permanent implant injected, under endoscopic visualization, around the urethra distal to the bladder neck. It is a composition of heat vulcanized, solid, soft, irregularly shaped polydimethylsiloxane (solid silicone elastomer) implants suspended in a biocompatible excretable carrier gel. Macroplastique does not degrade, is not absorbed into surrounding tissues and does not migrate from the implant site. The Company has sold Macroplastique for several urological indications in over 40 countries outside the United States.

Other Uroplasty Products

The Company markets outside of the United States minimally invasive products to address fecal incontinence. Its PTQ Implants offer minimally invasive, soft-textured permanent implant for treatment of fecal incontinence. The PTQ Implants are implanted circumferentially into the submucosa of the anal canal, creating a bulking and supportive effect similar to that of Macroplastique injection for the treatment of stress urinary incontinence. The PTQ is Conformite Europeenne (CE) marked and is sold outside the United States in various international markets. The Urgent PC is also CE marked and sold outside of the United States for the treatment of fecal incontinence. In addition to urological applications, the Company markets its tissue bulking material outside the United States for otolaryngology vocal cord rehabilitation applications under the trade name VOX Implants. In the Netherlands and the United Kingdom only, the Company distributes certain wound care products in accordance with a distributor agreement.

The Company competes with Pfizer Inc., Johnson and Johnson, Novartis, Allergan, GlaxoSmithKline, Carbon Medical Technologies, BioForm, Inc., Q-Med AB and Contura.

Advisors’ Opinion:

  • [By Lisa Levin]

    Uroplasty (NASDAQ: UPI) shares reached a new 52-week high of $5.22 after the company reported strong Q3 results.

    Juniper Networks (NYSE: JNPR) shares gained 8.23% to touch a new 52-week high of $28.15 after the company reported better-than-expected fourth-quarter results. Barclays upgraded the stock from Equalweight to Overweight and lifted the price target from $29.00 to $34.00.

Top Low Price Stocks To Buy Right Now: Umpqua Holdings Corp (UMPQ)

Umpqua Holdings Corporation (Umpqua) is a financial holding company. Umpqua has two principal operating subsidiaries, Umpqua Bank (the Bank) and Umpqua Investments, Inc. (Umpqua Investments). The Bank is primarily engaged in the business of commercial and retail banking and the delivery of retail brokerage services. The Bank provides a range of banking, wealth management, mortgage banking and other financial services to corporate, institutional and individual customers. Umpqua Investments is a broker-dealer and investment advisor with offices in Portland, Lake Oswego, Medford, Oregon, and in many Umpqua Bank stores. Umpqua Investments offers a range of investment products and services, including stocks, fixed income securities (municipal, corporate, and government bonds, Certificate of Deposits (CDs), and money market instruments), mutual funds, annuities, options, retirement planning, money management services and life insurance. In December 2011, the Bank launched a comm ercial real estate division. In November 2012, the Company acquired Circle Bancorp, parent company of Circle Bank. In July 2013, Umpqua Holdings Corp completed its acquisition of Financial Pacific Holding Corp.

The Company offers a Switch Kit, which allows a customer to open a primary checking account with Umpqua Bank in less than 10 minutes. Other avenues, through which customers can access its products, include its Website equipped with an e-switchkit, which includes Internet banking through umpqua.online, mobile banking, and its 24-hour telephone voice response system. Umpqua Private Bank serves high net worth individuals with liquid investable assets by providing customized financial solutions and offerings. Umpqua private bank works collaboratively with the Bank’s affiliate retail brokerage Umpqua Investments and with the independent capital management firm Ferguson Wellman Capital Management. Umpqua Investments provides a range of brokerage services, inc luding equity and fixed income products, mutual funds, annui! ties, options, retirement planning and money management services. Additionally, Umpqua Investments offers life insurance policies. At December 31, 2011, Umpqua Investments had 41Series seven-licensed financial advisors serving clients at three stand-alone retail brokerage offices and Investment Opportunity Centers located in many Bank stores.

Lending Activities

Umpqua offers loans for business and commercial customers, including accounts receivable and inventory financing, equipment loans, international trade, real estate construction loans and permanent financing and SBA program financing, as well as capital markets and treasury management. Additionally, it offers designed loan products for small businesses through its Small Business Lending Center. It also has a business banking division to increase lending to small and mid-sized businesses. The Company is also engaged in initiatives that continue to diversify the loan portfolio, including a focu s on commercial and industrial loans in addition to financing owner-occupied properties.

Real estate loans are available for construction, purchase and refinancing of residential owner-occupied and rental properties. Borrowers can choose from a variety of fixed and adjustable rate options and terms. It sells residential real estate loans that originate into the secondary market. It also supports the Home Affordable Refinance Program and Home Affordable Modification Program. The Bank also provide loans to individual borrowers for a variety of purposes, including secured and unsecured personal loans, home equity and personal lines of credit and motor vehicle loans. The Bank makes both secured and unsecured loans to individuals and businesses. During 2011, its commercial real estate, commercial, residential, and consumer and other represented approximately 64%, 25%, 10%, and 1%, respectively, of the total non-covered loan and lease portfolio.

Source of Funds

The Company offers an array of deposit p! roducts, ! including non-interest-bearing checking accounts, interest-bearing checking and savings accounts, money market accounts and certificates of deposit. These accounts earn interest at rates established by management based on market factors. It also offers a seniors program to customers over fifty years old, which includes an array of banking services and other amenities, such as purchase discounts, vacation trips and seminars.

Investment Activities

As of December 31, 2011, Umpqua’s portfolio of investments securities included securities issued by United States Treasury and agencies, and residential mortgage-backed securities and collateralized mortgage obligations. It also includes obligations of states and political subdivisions, other debt securities, and investments in mutual funds and other equity securities.

Advisors’ Opinion:

  • [By Roberto Pedone]

    Umpqua (UMPQ) is engaged in the business of commercial and retail banking and the delivery of retail brokerage services. This stock closed up 5% at $17.11 in Monday’s trading session.

    Monday’s Volume: 2.16 million

    Three-Month Average Volume: 686,781

    Volume % Change: 235%

    From a technical perspective, UMPQ ripped sharply higher here right off its 50-day moving average of $16.51 with strong upside volume. This move is quickly pushing shares of UMPQ within range of triggering a big breakout trade. That trade will hit if UMPQ manages to take out Monday’s intraday high of $17.46 and then once it clears its 52-week high at $17.48 with high volume.

    Traders should now look for long-biased trades in UMPQ as long as it’s trending above its 50-day at $16.51 or above more near-term support at $16 and then once it sustains a move or close above those breakout levels with volume that’s near or above 686,781 shares. If that breakout hits soon, then UMPQ will set up to enter new 52-week-high territory above, which is bullish technical price action. Some possible upside targets off that breakout are $20 to $23.

Top Low Price Stocks To Buy Right Now: OCI Resources LP (OCIR)

Oci Resources LP, incorporated on April 22, 2013, is a limited partnership formed by OCI Holdings to operate the trona ore mining and soda ash production business of OCI Wyoming. The Company owns a controlling 40.98% general partner interest and 10.02% limited partner interest in OCI Wyoming, serving a global market from its facility in the Green River Basin of Wyoming. As of March 31, 2013, OCI Wyoming had proven and probable reserves of approximately 267.1 million short tons of trona, which is equivalent to 145.5 million short tons of soda ash. During the year ended December 31, 2012, OCI Wyoming mined approximately 3.87 million short tons of trona and produced approximately 2.45 million short tons of soda ash.

Trona, a naturally occurring soft mineral, is also known as sodium sesquicarbonate and consists primarily of sodium carbonate, or soda ash, sodium bicarbonate and water. The Company process trona ore into soda ash, which is an essential raw material i n flat glass, container glass, detergents, chemicals, paper and other consumer and industrial products. The majority of the world’s trona reserves are located in the Green River Basin.

Advisors’ Opinion:

  • [By Robert Rapier]

    OCI Resources (NYSE: OCIR) is a subsidiary of Atlanta-based OCI Chemical, which operates the trona ore mining and soda ash production business of one of the largest and lowest cost natural soda ash producers in the world. The partnership debuted on Sept. 13 and had the worst opening day of any MLP IPO since 2010. On the first day of trading, units closed down more than 5 percent. They have since recovered, and now trade 6 percent above the IPO price.  Beginning with the quarter ending Dec. 31, 2013, OCIR intends to distribute at least the minimum quarterly distribution of $0.5000 per unit, or $2 on an annualized basis. At the recent unit closing price of $19.91, this corresponds to a prospective annual yield of 10 percent.

  • [By Renaissance Capital IPO Research]

    The following IPOs are expected to price this week:

    OCI Resources LP (OCIR), a north American soda ash production business of Korea’s OCI Chemical, plans to raise $100 million by offering 5.0 million shares at a price range of $19.00 to $21.00. At the midpoint of the proposed range, OCI Resources LP would command a market value of $399 million. OCI Resources LP, which was founded in 1962, booked $446 million in sales over the last 12 months. The Atlanta, GA-based company plans to list on the NYSE under the symbol OCIR. Citi and Goldman Sachs are the joint bookrunners on the deal.